1-15 of 15
Davide Melisi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

Timothy A. Yap, Maria Vieito, Capucine Baldini, Juan Manuel Sepúlveda-Sánchez, Shunsuke Kondo, Matteo Simonelli, Rasha Cosman, Andre van der Westhuizen, Victoria Atkinson, Antoine F. Carpentier, Mario Löhr, Rebecca Redman, Warren Mason, Andres Cervantes, Emilie Le Rhun, Sebastian Ochsenreither, Louise Warren, Yumin Zhao, Sophie Callies, Shawn T. Estrem, Michael Man, Leena Gandhi, Emin Avsar, Davide Melisi
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6666–6676.
https://doi.org/10.1158/1078-0432.CCR-21-1504
Published: 15 December 2021
View article titled, First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Open the PDF for First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer

Valeria Merz, Camilla Zecchetto, Raffaela Santoro, Francesca Simionato, Fabio Sabbadini, Domenico Mangiameli, Geny Piro, Alessandro Cavaliere, Michela Deiana, Maria Teresa Valenti, Diana Bazan, Vita Fedele, Sara Lonardi, Davide Melisi
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (17): 4661–4669.
https://doi.org/10.1158/1078-0432.CCR-20-0395
Published: 01 September 2020
View article titled, Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
Open the PDF for Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients

Carmine Carbone, Geny Piro, Francesca Simionato, Francesca Ligorio, Chiara Cremolini, Fotios Loupakis, Greta Alì, Daniele Rossini, Valeria Merz, Raffaela Santoro, Camilla Zecchetto, Marco Zanotto, Federica Di Nicolantonio, Alberto Bardelli, Gabriella Fontanini, Giampaolo Tortora, Davide Melisi
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4312–4322.
https://doi.org/10.1158/1078-0432.CCR-16-3153
Published: 01 August 2017
View article titled, Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients
Open the PDF for Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients in another window
Includes: Supplementary data
Journal Articles

A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer

Matthew P. Humphries, Sreekumar Sundara Rajan, Alastair Droop, Charlotte A.B. Suleman, Carmine Carbone, Cecilia Nilsson, Hedieh Honarpisheh, Gabor Cserni, Jo Dent, Laura Fulford, Lee B. Jordan, J. Louise Jones, Rani Kanthan, Maria Litwiniuk, Anna Di Benedetto, Marcella Mottolese, Elena Provenzano, Sami Shousha, Mark Stephens, Rosemary A. Walker, Janina Kulka, Ian O. Ellis, Margaret Jeffery, Helene H. Thygesen, Vera Cappelletti, Maria G. Daidone, Ingrid A. Hedenfalk, Marie-Louise Fjällskog, Davide Melisi, Lucy F. Stead, Abeer M. Shaaban, Valerie Speirs
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (10): 2575–2583.
https://doi.org/10.1158/1078-0432.CCR-16-1952
Published: 14 May 2017
View article titled, A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer
Open the PDF for A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer in another window
Includes: Supplementary data
Journal Articles

An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients

Geny Piro, Carmine Carbone, Ivana Cataldo, Federica Di Nicolantonio, Simone Giacopuzzi, Giuseppe Aprile, Francesca Simionato, Federico Boschi, Marco Zanotto, Maria Mihaela Mina, Raffaela Santoro, Valeria Merz, Andrea Sbarbati, Giovanni de Manzoni, Aldo Scarpa, Giampaolo Tortora, Davide Melisi
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (24): 6164–6175.
https://doi.org/10.1158/1078-0432.CCR-16-0178
Published: 15 December 2016
View article titled, An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients
Open the PDF for An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients in another window
Includes: Supplementary data
Journal Articles

IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation

Zhuonan Zhuang, Huai-Qiang Ju, Mitzi Aguilar, Takashi Gocho, Hao Li, Tomonori Iida, Harold Lee, Xiaoqiang Fan, Haijun Zhou, Jianhua Ling, Zhongkui Li, Jie Fu, Min Wu, Min Li, Davide Melisi, Yoichiro Iwakura, Kesen Xu, Jason B. Fleming, Paul J. Chiao
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (6): 1432–1444.
https://doi.org/10.1158/1078-0432.CCR-14-3382
Published: 14 March 2016
View article titled, IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
Open the PDF for IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation in another window
Includes: Supplementary data
Journal Articles

Abstract 26: Biomarker analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/RAD001

A. Rose Brannron, Davide Melisi, Jennifer Hummel, Carmine Carbone, Melissa Frizziero, Wing Cheung, Parul Patel, Jorge Gallo, Giampaolo Tortora, Michael Morrissey, David Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (1_Supplement): 26.
https://doi.org/10.1158/1557-3265.PMSCLINGEN15-26
Published: 03 January 2016
View article titled, Abstract 26: Biomarker analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/RAD001
Journal Articles

Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers

Roberta Rosa, Davide Melisi, Vincenzo Damiano, Roberto Bianco, Sonia Garofalo, Teresa Gelardi, Sudhir Agrawal, Federica Di Nicolantonio, Aldo Scarpa, Alberto Bardelli, Giampaolo Tortora
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (20): 6531–6541.
https://doi.org/10.1158/1078-0432.CCR-10-3376
Published: 14 October 2011
View article titled, Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in <em>K</em>-<em>Ras</em> Mutant Colorectal and Pancreatic Cancers
Open the PDF for Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in <em>K</em>-<em>Ras</em> Mutant Colorectal and Pancreatic Cancers in another window
Includes: Supplementary data
Journal Articles

Anti-VEGF Treatment–Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype

Carmine Carbone, Tania Moccia, Cihui Zhu, Genni Paradiso, Alfredo Budillon, Paul J. Chiao, James L. Abbruzzese, Davide Melisi
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (17): 5822–5832.
https://doi.org/10.1158/1078-0432.CCR-11-1185
Published: 01 September 2011
View article titled, Anti-VEGF Treatment–Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype
Open the PDF for Anti-VEGF Treatment–Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype in another window
Includes: Supplementary data
Journal Articles

Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity

Davide Melisi, Valeria Ossovskaya, Cihui Zhu, Roberta Rosa, Jianhua Ling, Patrick M. Dougherty, Barry M. Sherman, James L. Abbruzzese, Paul J. Chiao
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (20): 6367–6377.
https://doi.org/10.1158/1078-0432.CCR-09-0910
Published: 14 October 2009
View article titled, Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity
Open the PDF for Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity in another window
Includes: Supplementary data
Journal Articles

Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells

Roberto Bianco, Roberta Rosa, Vincenzo Damiano, Gennaro Daniele, Teresa Gelardi, Sonia Garofalo, Valeria Tarallo, Sandro De Falco, Davide Melisi, Roberto Benelli, Adriana Albini, Anderson Ryan, Fortunato Ciardiello, Giampaolo Tortora
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (16): 5069–5080.
https://doi.org/10.1158/1078-0432.CCR-07-4905
Published: 12 August 2008
View article titled, Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
Open the PDF for Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma

Vincenzo Damiano, Davide Melisi, Cataldo Bianco, David Raben, Rosa Caputo, Gabriella Fontanini, Roberto Bianco, Anderson Ryan, A. Raffaele Bianco, Sabino De Placido, Fortunato Ciardiello, Giampaolo Tortora
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (15): 5639–5644.
https://doi.org/10.1158/1078-0432.CCR-05-0174
Published: 01 August 2005
View article titled, Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma
Open the PDF for Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma in another window
Journal Articles

Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy

Fortunato Ciardiello, Roberto Bianco, Roberta Caputo, Rosa Caputo, Vincenzo Damiano, Teresa Troiani, Davide Melisi, Ferdinando De Vita, Sabino De Placido, A. Raffaele Bianco, Giampaolo Tortora
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (2): 784–793.
https://doi.org/10.1158/1078-0432.CCR-1100-03
Published: 03 February 2004
View article titled, Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy
Open the PDF for Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy in another window
Journal Articles

Combination of a Selective Cyclooxygenase-2 Inhibitor with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 and Protein Kinase A Antisense Causes Cooperative Antitumor and Antiangiogenic Effect

Giampaolo Tortora, Rosa Caputo, Vincenzo Damiano, Davide Melisi, Roberto Bianco, Gabriella Fontanini, Bianca Maria Veneziani, Sabino De Placido, A. Raffaele Bianco, Fortunato Ciardiello
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (4): 1566–1572.
Published: 01 April 2003
View article titled, Combination of a Selective Cyclooxygenase-2 Inhibitor with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 and Protein Kinase A Antisense Causes Cooperative Antitumor and Antiangiogenic Effect
Open the PDF for Combination of a Selective Cyclooxygenase-2 Inhibitor with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 and Protein Kinase A Antisense Causes Cooperative Antitumor and Antiangiogenic Effect in another window
Journal Articles

Oral Administration of a Novel Taxane, an Antisense Oligonucleotide Targeting Protein Kinase A, and the Epidermal Growth Factor Receptor Inhibitor Iressa Causes Cooperative Antitumor and Antiangiogenic Activity

Giampaolo Tortora, Rosa Caputo, Vincenzo Damiano, Gabriella Fontanini, Davide Melisi, Bianca Maria Veneziani, Franco Zunino, A. Raffaele Bianco, Fortunato Ciardiello
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (12): 4156–4163.
Published: 01 December 2001
View article titled, Oral Administration of a Novel Taxane, an Antisense Oligonucleotide Targeting Protein Kinase A, and the Epidermal Growth Factor Receptor Inhibitor Iressa Causes Cooperative Antitumor and Antiangiogenic Activity
Open the PDF for Oral Administration of a Novel Taxane, an Antisense Oligonucleotide Targeting Protein Kinase A, and the Epidermal Growth Factor Receptor Inhibitor Iressa Causes Cooperative Antitumor and Antiangiogenic Activity in another window